Registration Header

Date:December 1, 2021

Start Time:10:00am CT (Chicago) | 5:00pm CET (Paris)

Duration:60 minutes


The pipeline of advanced therapy is expanding at a rate never seen before, with a number of cell and gene therapies now reaching the market. As a result, the services required to develop them are in more demand than ever. In this webinar we take a look at some of the promising therapies in development, and what is needed to ensure reliable, consistent and scalable manufacturing so that the price of these treatments can be reduced and they can become mainstream.




Arun Upadhyay, PhD

Vice President and Head of R&D


Dr Arun Upadhyay is vice president and head of research & development at Ocugen. In this role, he oversees the biotech’s efforts in discovery research and innovation, early- to late-stage global product development, and a supply chain program that specifically supports its clinical trials, including leading a team of scientists that is exploring how gene modifier therapeutic technology can transform the treatment of degenerative diseases. Dr Upadhyay has over 15 years of experience ranging from discovery research, manufacturing, and clinical trial supply management. He has worked extensively in drug development, from small molecules to biologics, and advanced cell and gene therapy modalities. Prior to joining Ocugen, he led ophthalmic drug development and delivery research at the University of Colorado Denver in the Department of Pharmaceutical Sciences. There, he was instrumental in developing novel approaches for sustained and targeted drug delivery of peptide, proteins, RNA, and DNA to cells and tissues.

Sanjay Srivastava, PhD

Managing Director, Cell & Gene Therapy CoE Lead


A senior management consultant with over 20 years of life sciences and health care experience. Sanjay is driving Accenture’s global Cell & Gene therapy CoE and consulting practice. He helps biopharma and biotech companies define and implement fundamentally new and transformative capabilities to develop, manufacture, and commercialize therapies in new modalities. He assist clients to design and develop global patient operations, supply chain operations and go to market stakeholder engagement models.

Matthew Durdy


Cell and Gene Therapy Catapult

Matthew Durdy is Chief Executive of the Cell and Gene Therapy Catapult, having been part of the founding team in 2012. Prior to 2020, he was Chief Business Officer and was responsible for strategy, communications, marketing, and business development. He is credited with leading the design and implementation of the commercial model for the highly successful Cell and Gene Therapy Catapult manufacturing centre and being a global champion for the early integration of healthcare economics and reimbursement expertise into decision-making and clinical product design. He began his career in international investment banking and venture capital, and has successfully invested in and managed a number of biotechnology SMEs and regional operations of multinational organisations. He has an MA from the University of Oxford in Pure and Applied Biology, an MBA from the University of Chicago, and is a Fellow of the Chartered Institute for Securities and Investment. He is also Vice Chair of the Board of Trustees of the charity Parkinson’s UK.

Jane Byrne

Senior Editor - Host


Jane has more than 15 years of experience as a journalist on news titles and trade press. She now writes about the international biopharmaceutical industry: including vaccine development, biosimilars, cell and gene therapies and the regulatory landscape.

First Name
Last Name
Email Address
Business Activity
Job Title
Company Employees

Got a burning question about this topic? Send it to us using the box below and we will try to have it answered by our expert panelists. You are also welcome to ask questions on the live day

This Editorial Webinar is a free service provided to you by BioPharma-Reporter. This service is sponsored by the partners named on this page and they would like to contact you about their products and services. Please let us know if you are happy for our partners to contact you:

By email:

BioPharma-Reporter may use your contact data to keep you informed of its products and services by email or by phone. You can withdraw your marketing consent at any time by clicking the unsubscribe link in such email or by sending an email to

More information on our processing can be found in our Privacy Notice. By submitting this form, you acknowledge that you have read and understand our Privacy Notice